The emerging role of epigenetic therapeutics in immuno-oncology
Nature Reviews Clinical Oncology, Published online: 23 September 2019; doi:10.1038/s41571-019-0266-5Despite promising responses in a minority of patients with cancer, considerable scope remains to improve the efficacy of both immune-checkpoint inhibitors and epigenetic drugs, with one potential strategy involving the combination of these two types of treatment. Here, the authors describe the mechanisms underlying the synergy between immune-checkpoint inhibitors and epigenetic drugs and discuss the ongoing clinical development of such combinations.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Michael J. Topper Michelle Vaz Kristen A. Marrone Julie R. Brahmer Stephen B. Baylin Source Type: research
More News: Cancer | Cancer & Oncology